Research programme: caspase stimulants - Novelix

Drug Profile

Research programme: caspase stimulants - Novelix

Alternative Names: NVX-207

Latest Information Update: 14 Jan 2014

Price : $50

At a glance

  • Originator University of Southern California
  • Developer Novelix Pharmaceuticals
  • Class Sterols
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Caspase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Actinic keratosis; Cancer

Most Recent Events

  • 25 Aug 2009 Preclinical development is ongoing in USA
  • 01 May 2009 Pharmacodynamics data from a preclinical trial in Cancer released by Novelix Pharmaceuticals
  • 28 Feb 2007 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top